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Abstract	
Type	1	diabetes	is	an	autoimmune	condition	characterised	by	a	pancreatic	insulin	secretion	
deficit,	 resulting	 in	 high	 blood	 glucose	 concentrations,	 which	 can	 lead	 to	 micro-	 and	
macrovascular	 complications.	 Type	1	diabetes	also	 leads	 to	 impaired	glucagon	production	
by	the	pancreatic	α-cells,	which	acts	as	a	counter-regulatory	hormone	to	insulin.		
A	 closed-loop	 system	 for	 automatic	 insulin	 and	 glucagon	 delivery,	 also	 referred	 to	 as	 an	
artificial	 pancreas,	 has	 the	 potential	 to	 reduce	 the	 self-management	 burden	 of	 type	 1	
diabetes	and	reduce	the	risk	of	hypo-	and	hyperglycemia.	To	date,	bihormonal	closed-loop	
systems	for	glucagon	and	insulin	delivery	have	been	based	on	two	independent	controllers.	
However,	 in	 physiology,	 the	 secretion	 of	 insulin	 and	 glucagon	 in	 the	 body	 is	 closely	
interconnected	by	paracrine	and	endocrine	associations.	 In	 this	work,	we	present	a	novel	
biologically-inspired	glucose	control	strategy	that	accounts	for	such	coordination.	
An	 in-silico	 study	using	an	FDA-accepted	 type	1	 simulator	was	performed	 to	evaluate	 the	
proposed	 coordinated	 control	 strategy	 compared	 to	 its	 non-coordinated	 counterpart.	 The	
proposed	 coordinated	 strategy	 achieves	 a	 reduction	 of	 hyperglycemia	 without	 increasing	
hypoglycemia,	when	compared	to	its	non-coordinated	counterpart.	
	
1. Introduction	
Glucose	metabolism	in	humans	is	tightly	controlled	by	several	feedback	mechanisms	that	
provide	high	robustness	to	prevent	undesirable	fluctuations	(i.e.	hyperglycemia	or	
hypoglycemia).	In	these	feedback	mechanisms,	many	interconnected	biological	signals	such	
as	different	hormones	(e.g.	insulin,	glucagon)	and	neurotransmitters	are	involved	
[Wasserman	2009].	
In	addition	to	insulin	and	glucagon,	which	are	the	most	 important	hormones	that	regulate	
glucose	 concentrations,	 there	 are	 many	 other	 substances	 that	 have	 to	 be	 taken	 into	
account.	 The	primary	 glycohormones	 are	 insulin,	 glucagon,	 amylin	 and	 incretin	hormones	
(GLP-1	 and	 GIP),	 which	 are	 secreted	 by	 the	 pancreas	 and	 the	 gut.	 Moreover,	 both	 the	
Central	 Nervous	 System	 and	 the	 Autonomic	 Nervous	 System	 (sympathetic	 and	
parasympathetic)	are	implied	directly	and	indirectly	in	the	regulation	mechanisms	of	glucose	
(Figure	 1).	 However,	 the	 central	 axis	 of	 the	 regulation	 is	 the	 interaction	 between	insulin	
secreting	pancreatic	β-cells	and	the	glucagon	secreting	pancreatic	α-cells.		
	
Figure	1.	Global	Hormone	and	Neurotransmitter	interactions.	ANS	(Autonomic	Nervous	
System),	Ach	(Acetylcholine),	NA	(Noradrenaline).	Arrows	indicate	a	potentiation	effect	and	
circles	a	suppressive	effect.		
Diabetes	mellitus	 is	a	chronic	condition	that	occurs	either	when	the	pancreatic	β-cells	can	
no	longer	produce	sufficient	insulin	due	to	autoimmune	destruction	(type	1),	or	when	there	
is	 a	 decreased	 cellular	 response	 to	 circulating	 insulin	 (type	 2).	 The	 resulting	 absolute	 or	
relative	deficiency	of	insulin	causes	hyperglycaemia	(high	blood	glucose),	which	can	lead	to	
micro-	 and	 macro	 vascular	 complications	 including	 blindness,	 kidney	 failure,	 limb	
amputation,	and	cardiovascular	disease.	Type	1	diabetes	mellitus	(T1DM)	may	also	lead	to	
impaired	 glucagon	 production	 by	 the	 α-cells,	 which	 is	 the	 primary	 counter-regulatory	
hormone	to	insulin.		
Current	therapy	for	T1DM	consists	of	measuring	blood	glucose	levels	by	means	of	a	glucose	
meter	and	 injecting	multiple	daily	doses	of	 insulin	 to	keeps	glucose	 levels	 in	a	safe	 range.	
However,	 many	 people	 with	 T1DM	 using	 this	 therapy	 do	 not	 achieve	 the	 recommended	
glycemic	targets	[DCCT	1991].	
	
One	solution	to	reduce	the	burden	of	self-management	of	T1DM,	as	well	as	to	significantly	
improve	 glycemic	 control,	 is	 a	 closed-loop	 system	 for	 automatic	 insulin	 delivery	 [Kropff	
2016],	also	referred	to	as	an	artificial	pancreas.		
The	 most	 common	 configuration	 of	 artificial	 pancreas	 consists	 of	 a	 subcutaneous	
continuous	glucose	sensor	which	measures	interstitial	glucose	levels	every	five	minutes	and	
a	 subcutaneous	 insulin	 pump	 that	 delivers	 insulin	 at	 a	 rate	 computed	 by	 a	 closed-loop	
controller	[Doyle	2014]	(Figure	2).		
Due	to	the	delays	in	subcutaneous	insulin	absorption,	most	of	the	current	artificial	pancreas	
systems	 include	 a	 feed-forward	 control	 strategy	 consisting	 of	 a	 pre-meal	 insulin	 bolus	 to	
compensate	 for	 perturbations	 caused	 by	 the	 meals	 as	 well	 as	 an	 insulin	 feedback	
mechanism	 to	 take	 into	 account	 the	 insulin	 still	 active	 in	 the	 body	 (i.e.	 insulin-on-board)	
[Doyle	2014].	
	
Figure	2.	Block	diagram	of	a	closed-loop	system	for	glucose	control	incorporating	a	meal	
bolus	calculator.	
Another	 configuration	 of	 artificial	 pancreas	 consists	 of	 a	 bihormonal	 closed-loop	 system	
incorporating	insulin	and	glucagon	delivery	[Russell	2014].	 	This	system	has	the	advantage	
of	 accounting	 for	 the	 counter-regulatory	 action	 to	 insulin,	 which	might	 be	 very	 useful	 in	
certain	 situations	 such	 as	 following	 exercise	 [Taleb	2016].	However,	 the	need	 for	 a	more	
complex	 system	 incorporating	 two	 infusion	 systems,	 and	 the	 lack	 of	 a	 commercial	 stable	
glucagon	solution,	makes	 this	control	 strategy	potentially	more	challenging.	Despite	 these	
challenges,	 there	 are	 at	 least	 three	 companies	 that	 are	 currently	 working	 on	 a	 stable	
glucagon	solutions	(Zealand,	Xeris,	and	Adocia)	which	have	reported	to	be	in	the	latest	stage	
of	 development.	 In	 addition,	 there	 are	 two	 companies	 developing	 prototypes	 of	 dual-
chamber	 bihormonal	 artificial	 pancreas	 (Beta-bionic	 and	 Inreda)	 which	 plan	 to	 have	
regulatory	submissions	in	2017	[Ginsberg	2017].	
	
To	date,	most	bihormonal	closed-loop	systems	for	glucagon	and	insulin	delivery	have	been	
based	on	two	independent	controllers	(e.g.	MPC+PD	[Russell	2014],	PID+PID	[Jacobs	2014]	
[Taleb	 2016])	 (Figure	 3).	 	 However,	 it	 is	 well	 known	 that	 the	 secretion	 of	 these	 two	
hormones	in	the	body	is	closely	interconnected	through	potentiation	of	insulin	secretion	by	
plasma	 glucagon	 levels	 and	 a	 suppression	 of	 glucagon	 secretion	 by	 plasma	 insulin	 levels	
[Wasserman	2009].	
	
Figure	3:	Graphical	representation	of	the	bihormonal	control	strategy	where	the	two	
controllers	are	completely	independent.	
	
In	 this	 work,	 we	 present	 a	 novel	 biologically	 inspired	 bihormonal	 closed-loop	 control	
strategy	that	accounts	for	such	coordination.	
	
2. Methods	
Although	 the	 inter-relation	between	 insulin	 and	glucagon	 secretion	 is	 known	 to	be	highly	
complex	[Wasserman	2009],	this	work	focuses	on	accounting	for	the	potentiation	effect	of	
insulin	 secretion	 by	 plasma	 glucagon	 levels.	 The	 rationale	 behind	 considering	 such	
interaction	 in	 a	 closed-loop	 system	 is	 to	 anticipate	 the	 glucose	 increase	 after	 glucagon	
secretion	and	therefore	minimize	a	rebound	in	hyperglycemia.	
To	account	 for	 such	effect,	 the	 insulin	delivered	due	 to	 the	potentiation	effect	by	plasma	
glucagon	 levels	 is	 proportional	 to	 the	 delivered	 glucagon.	 More	 specifically,	 glucagon	 is	
integrated	from	the	time	it	is	started	being	delivered	to	the	time	its	delivery	stops.	Then,	the	
resulting	 glucagon	 dose	 is	 multiplied	 by	 a	 correction	 factor	 (KC)	 (Figure	 4).	 This	 can	 be	
expressed	as	 							𝐼𝑛𝑠𝑢𝑙𝑖𝑛() 𝑡 = 𝐾𝐶 𝐺𝑙𝑢𝑐𝑎𝑔𝑜𝑛(𝜏)𝑑𝜏7879 ,	 	 (1)	
where	 InsulinGN	 is	 the	 insulin	 delivered	due	 to	 the	 glucagon	potentiation,	Glucagon	 is	 the	
glucagon	delivered	by	the	glucagon	controller,	t0	is	the	time	glucagon	starts	being	delivered	
to	prevent	hypoglycemia,	tn	is	the	time	glucagon	stops	and	KC	is	a	correction	factor	defined	
as	 𝐾𝐶 = 𝐾 (;<=;< ,	 	 (2)	
where	 ISF	 is	 the	 insulin	 sensitivity	 factor,	GSF	 is	 the	glucagon	 sensitivity	 factor	 and	K	 is	 a	
tuning	gain.	Note	that,	unlike	the	ISF,	the	glucagon	sensitivity	factor	is	not	a	commonly	used	
parameter	 in	diabetes	management	practice.	However,	 this	parameter	can	be	obtained	 in	
the	same	way	ISF	is	obtained,	i.e.	measuring	the	glucose	increase	in	fasting	conditions	after	
the	administration	of	a	standardized	glucose	dose.	
Then,	the	total	insulin	sent	to	the	pump	is	expressed	as	𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝑡 = 𝐼𝑛𝑠𝑢𝑙𝑖𝑛> 𝑡 + 	𝐼𝑛𝑠𝑢𝑙𝑖𝑛() 𝑡 − 	𝐼𝑛𝑠𝑢𝑙𝑖𝑛<A 𝑡 ,		 	 (3)	
where	Insulin0	is	the	insulin	proposed	by	the	controller	(e.g.	PID)	and	InsulinFB	is	the	insulin	
feedback	term	implemented	in	many	of	existing	controllers	[Doyle	2014].	
	
	
Figure	4:	Graphical	representation	of	the	bihormonal	control	strategy	incorporating	the	
potentiation	effect	of	insulin	secretion	by	plasma	glucagon	levels.	
	
For	evaluation	purposes,	an	updated	version	of	 Imperial	College	Artificial	Pancreas	 (ICAP),	
also	referred	to	as	Bio-inspired	Artificial	Pancreas	(BiAP),	controller	was	employed	for	insulin	
delivery.	 For	 the	 sake	 of	 simplicity,	 the	 existing	 controller	 in	 the	 ICAP	 was	 selected	 for	
glucagon	 delivery.	 It	 is	 important	 to	 note	 that	 proposed	 coordination	 strategy	 is	
independent	of	the	employed	controllers	and	can	be	generalized	for	any	artificial	pancreas	
system.	
	
The	Imperial	College	Artificial	Pancreas	Controller	
The	 Imperial	 College	 Artificial	 Pancreas	 (ICAP)	 controller,	 also	 referred	 to	 as	 Bio-inspired	
Artificial	Pancreas	(BiAP),	has	been	previously	in	silico	[Herrero	2012]	and	clinically	validated	
[Reddy	2014,	Reddy	2015].	ICAP	uses	a	pancreatic	insulin	secretion	model	[Pedersen	2010]	
as	a	core	component	to	emulate	the	behavior	of	a	healthy	𝛽-cell.	In	this	work,	such	model	
has	 been	 updated	with	 a	more	 recent	 one	 [Riz	 2014]	 that	was	 proven	 to	 provide	 better	
performance	in	simulation	studies,	as	well	as	to	reduce	the	computational	complexity	of	the	
controller.		
Similar	 to	most	 of	 the	 existing	 glucose	 controllers,	 ICAP	 incorporates	 an	 insulin	 feedback	
term	 [Doyle	 2014]	 to	 avoid	 insulin	 stacking	 by	 compensating	 for	 delays	 associated	 with	
subcutaneous	 insulin	delivery,	and	a	 feedforward	strategy	consisting	of	a	pre-meal	 insulin	
bolus	calculator	[Doyle	2014]	to	tackle	the	perturbation	introduced	by	meal	intake.		
The	employed	glucagon	controller	uses	the	same	secretion	model	employed	 in	the	 insulin	
controller	 and	 a	 glucagon	 feedback	 term	 to	 avoid	 glucagon	 stacking	 associated	 with	 the	
subcutaneous	delivery.	Figure	5	shows	a	schematic	diagram	of	the	proposed	controller.	
	
Figure	5.	Block	diagram	of	the	non-coordinated	ICAP	controller,	where	inputs	are	the	
amount	of	ingested	carbohydrates,	the	glucose	concentration	from	a	continuous	glucose	
sensor,	and	the	basal	insulin	rate	for	a	given	subject,	and	the	output	in	the	insulin	dose	to	
be	delivered	by	the	insulin	pump.	
	
The	insulin	controller	is	described	by	the	equation	𝐼𝑛𝑠𝑢𝑙𝑖𝑛 𝑡 = 𝑆𝑅 𝑡 +	𝑆𝑅E(𝑡) + 𝐵𝑜𝑙𝑢𝑠(𝑡) − 𝐾G𝐼(𝑡),		 (4)	
where	SR	 is	 the	pancreatic	 insulin	secretion	above	basal	 secretion;	SRb	 is	 the	basal	 insulin	
secretion,	which	is	set	to	the	subject’s	basal	 insulin	profile;	and	Bolus	 is	a	pre-meal	 insulin	
bolus	calculated	as		 𝐵𝑜𝑙𝑢𝑠 𝑡 = HIJE 7=HK +	(LMNOPQ 7 R(ST=;< ,	 	 (5)	
where	Carbs	 is	the	amount	of	 ingested	carbohydrates,	 ICR	 is	the	patient	specific	 insulin	to	
carbohydrate	 ratio,	 Gsp	 is	 the	 glucose	 set-point	 and	 ISF	 is	 the	 patient	 specific	 insulin	
sensitivity	factor.	
The	 insulin	 feedback	 term	 𝐾G𝐼	 is	 proportional	 (𝐾G)	 to	 the	 plasma	 insulin	 estimation	𝐼	computed	using	the	insulin	pharmacokinetic	[Hovorka	2004]	model	
𝐼 𝑡 = 	−𝑘Q	𝐼 𝑡 +	 ;V 7WX	7YZ[X	,			 	 	 (6)	𝑆\(𝑡) = 𝑢 𝑡 −	 ;] 77YZ[X	,	 	 	 	 (7)	𝑆^ = 	 ;] 7 R;V(7)7YZ[X 	,	 	 	 	 	 (8)	
where,	𝑘Q	is	the	first	order	decay	rate	for	insulin	in	plasma,	𝑢	subcutaneous	insulin	infusion	
rate,	𝑉=	 is	 the	distribution	volume	of	plasma	 insulin,	𝑡`Ia=	 is	 the	time-to-maximum	insulin	
absorption,	 𝑆\	 and	 𝑆^	 are	 a	 two-compartment	 chain	 representing	 absorption	 of	
subcutaneously	administered	insulin.	
As	described	in	[Riz	2014],	the	pancreatic	insulin	secretion	(SR)	above	basal	secretion	(SRb)	is	
assumed	proportional	(m)	to	the	amount	X	of	readily	releasable	insulin	in	the	beta-cells	𝑆𝑅(𝑡) = 𝑚	𝑋(𝑡).		 (9)	
The	 change	 in	 the	 insulin	 amount	 in	 the	 ready	 releasable	 pool	 (RRP)	 X	 results	 from	 the	
balance	 between	 the	 insulin	 secretion	 rate,	 the	 provision	 Y	 of	 insulin	 refilling	 the	 readily	
releasable	pool,	and	recruitment	of	readily	releasable	insulin	XD		de(7)d7 = −𝑚𝑋(𝑡) + 𝑌(𝑡) + 𝑋g(𝑡),									𝑋(0) = 0,	 (10)	
where	XD	is	responsible	for	the	first	phase	of	secretion	and	is	assumed	to	be	proportional	to	
the	rate	of	increase	of	glucose	via	the	constant	parameter	KD	and	expressed	as	𝑋g(𝑡) 	= 	 𝐾g d( 7d7 , 𝑖𝑓	 d( 7d7 > 0;0,																		𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 	 	 	(11)	
In	 this	work,	 the	 conditional	 statement	 in	Equation	 (11)	 regarding	 the	 sign	of	 the	glucose	
derivative	 was	 eliminated.	 The	 reason	 for	 this	 modification	 is	 that	 delays	 in	 insulin	
absorption	 and	 glucose	 sensing	 due	 to	 the	 subcutaneous	 route	 make	 reducing	 insulin	
delivery	when	glucose	is	dropping	desirable	in	order	to	minimize	hypoglycemia.		
The	provision	Y	generates	the	slower	second	phase	of	insulin	secretion	and	is	controlled	by	
glucose	according	to	the	equation	dp(7)d7 = −𝛼 𝑌(𝑡) 	− 	𝛽(𝐺(𝑡) 	−	𝐺E) ,									𝑌(0) = 0,	 (12)	
where	Gb	represents	the	basal	value	of	glucose,	and	𝛼	and	𝛽	are	parameters.	
Parameter	𝛽	is	employed	as	a	personalized	tunable	gain	proportional	to	the	subject’s	insulin	
sensitivity	factor	(ISF)	used	to	overcome	inter-subject	variability.		
To	 minimize	 hypoglycemia,	 a	 simple	 low-glucose	 insulin	 suspend	 (LGS)	 mechanism	 was	
incorporated	which	reduces	basal	insulin	delivery	(𝑆𝑅E)	to	50%	if	the	glucose	falls	below	a	
predefined	threshold	(100	mg/dl)	and	suspends	the	insulin	delivery	if	it	falls	below	a	second	
lower	predefined	threshold	(80mg/dl).	
The	 employed	 glucagon	 controller	 uses	 the	 same	 secretion	 and	 pharmacokinetic	 model	
structure	 used	 in	 the	 insulin	 controller,	 but	 with	 different	 parameters	 (see	 Table	 1).	 The	
glucagon	controller	is	described	by	the	equation	𝐺𝑙𝑢𝑐𝑎𝑔𝑜𝑛 𝑡 = 𝑆𝑅′ 𝑡 − 𝐾G′𝑁(𝑡),		 (13)	
where	 SR’	 is	 the	 pancreatic	 glucagon	 secretion	 above	 basal	 secretion	 and	 𝐾G′𝑁	 is	
proportional	 (𝐾G)	 to	 the	 plasma	 glucagon	 estimation	 (N)	 computed	 using	 the	 same	
pharmacokinetic	model	used	for	insulin	absorption	[Herrero	2013].	
Since	 delays	 in	 glucagon	 absorption	 are	 significantly	 smaller	 than	 delays	 in	 insulin	
absorption,	Equation	(11)	was	kept	as	in	the	original	model	proposed	by	Riz	et	al.	[Riz	2014].	
For	simulation	purposes,	all	 the	differential	equations	of	the	model	were	discretized	using	
Euler	method	with	an	integration	step	of	one	minute.	
	
Controllers	tuning	
Controller	 parameters	 were	 fixed	 to	 the	 same	 value	 except	 parameters	 b	 (b’	 for	 the	
glucagon	 controller),	which	was	used	 to	personalize	 the	 controller	 to	each	 individual	 (see	
Table	1).	These	 two	parameters	were	 then	correlated	 to	 the	 insulin	 sensitivity	 factor	 (ISF)	
and	the	glucagon	sensitivity	factor	(GSF)	of	the	subject	 in	order	to	provide	an	easy	way	to	
tune	 the	 controller.	With	 such	 configuration,	 both	 single-hormone	 controllers	 (i.e.	 insulin	
and	 glucagon	 controllers)	were	manually	 tuned	 in	 a	 non-coordinated	way	 to	 achieve	 the	
best	 possible	 glycemic	 outcome	 over	 one-week	 scenario.	 In	 particular,	 two	 standard	
glycemic	 metrics	 were	 employed	 for	 such	 purpose;	 maximizing	 the	 percentage	 time	 in	
target	 range	 [70,180]	mg/dl	 and	minimizing	 the	 percentage	 time	 below	 target	 70	mg/dL	
[Maahs	2016].	
Figure	 5	 shows	 a	 graphical	 representation	 of	 the	 correlation	 GSF	 vs.	 b’	 (b’=0.046*GSF,	
R2=0.85).	
	
Figure	5.	Graphical	representation	of	the	correlation	GSF	vs.	b’	
	
It	is	important	to	note	that	the	tuning	of	the	insulin	and	glucagon	controllers	was	exactly	the	
same	for	both	the	non-coordinated	and	coordinated	strategies.	
Table	1	shows	the	parameters	for	the	insulin	and	glucagon	controllers.	The	parameters	for	
the	 insulin	 absorption	 model	 were	 taken	 from	 [Hovorka	 2004].	 The	 parameters	 for	 the	
plasma	 absorption	 models	 with	 plasma	 glucagon	 absorption	 model	 were	 obtained	 by	
identifying	the	pharmacokinetic	model	using	mean	population	subject	from	the	UVa-Padova	
T1DM	simulator	(v3.2).	Finally,	the	coordination	gain	was	set	to	K	=	2.5.	
	
Table	1.	Tuning	parameters	employed	for	the	insulin	and	glucagon	controllers.	
Parameter	 Insulin	controller	 Glucagon	controller	
m	 0.5	 0.5	
a	 m	 m	
b	(U	per	mg/dl	and	mg	per	
mg/dl)	
0.0215/ISF	 0.0039/GSF	(adults)	
0.005/GSF	(adolescents	
and	children)	
KD	(min)	 b·45	 b·30	
Gb	(mg/dl)	 117	 117	
Ky	 50	 10	
ke	(min-1)	 0.138	 0.1	
tmax	(min)	 54	 30	
V	(dl)	 12	 12	
	
In	Silico	Evaluation	under	intra-day	variability	
The	 UVa-Padova	 T1DM	 simulator	 (v3.2)	 [Kovatchev	 2009]	 was	 used	 to	 evaluate	 the	
proposed	 coordinated	 bihormonal	 closed-loop	 control	 strategy.	 A	 virtual	 cohort	 of	 10	
adults,	10	adolescents	and	10	children,	plus	their	corresponding	average	subject,	were	used	
for	this	purpose.		
The	 chosen	 basal	 insulin	 infusion	 rates	 were	 the	 ones	 provided	 by	 the	 simulator.	 The	
selected	CGM	and	insulin	pump	models	were	the	Dexcom	G4	and	Deltec	Cozmo.		
Intra-day	variability	was	introduced	to	the	simulator	by	modifying	some	of	the	parameters	
of	the	model	described	in	[Dalla	Man	2007].	In	particular,	meal	variability	was	emulated	by	
introducing	meal-size	variability	(CV=10%),	meal-time	variability	(STD=20)	and	uncertainty	in	
the	 carbohydrate	 estimation	 (uniform	 distribution	 between	 -30%	 and	 +40%)	 [Brazeau	
2013].	 Variability	 of	 meal	 absorption	 rate	 (kabs)	 and	 carbohydrate	 bioavailability	 (f)	 were	
considered	to	be	±30%	and	±10%	respectively.	To	emulate	intra-day	meal	variability,	the	11	
meals	 corresponding	 to	 each	 cohort	 were	 randomly	 assigned	 at	 each	meal	 intake.	 Intra-
subject	 variability	 in	 insulin	 absorption	model	 parameter	 (kd,	 ka1,	 ka2)	was	 assumed	 ±30%	
[Haidar	2013].	Insulin	sensitivity	parameters	(Vmx,	Kp3)	were	assumed	to	vary	along	the	day	
following	the	sinusoidal	pattern	𝑝 𝑡 = 𝑝> + 0.3 · 𝑝>𝑠𝑖𝑛 2 y^z·{> 𝑡 + 2𝜋 · 𝑅𝑁𝐷,	 	 (14)	
where	p(t)	 is	 the	 corresponding	 time	varying	parameter	 (i.e.	Vmx	 or	kp3);	 p0	 is	 the	default	
parameter	 value	 in	 the	 simulator;	 and	 RND	 is	 a	 randomly	 uniformly	 generated	 number	
between	 0	 and	 1.	 The	 selected	 daily	 pattern	 of	 carbohydrate	 doses	was	 7am	 (50g),	 1pm	
(80g),	5pm	(30g),	8pm	(60g).		
Physical	 exercise	was	 simulated	 using	 the	model	 introduced	 by	 Schiavon	 et	 al.	 [Schiavon	
2013].	 Although	 not	 being	 very	 realistic	 for	 most	 people	 with	 type	 1	 diabetes,	 a	 daily	
exercise	 at	 15:00h	 (STD=20min),	 intensity	 of	 50%	 VO2max	 (CV=10)	 and	 a	 duration	 of	 60	
minutes	(CV=10)	was	employed	for	this	purpose.		
The	 following	 standard	 glycemic	 control	 metrics	 [Maahs	 2016]	 were	 selected	 for	
comparison	purposes:	mean	blood	glucose	(BG);	percentage	time	in	target	ranges	[70,140]	
and	 [70,180]	mg/dl	 (%inT);	 percentage	 time	below	 target	 (%<70);	 percentage	 time	 above	
targets	 (%>140	 and	%>180);	 standard	 deviation	 (STD);	 risk	 index	 (RI);	 low	 blood	 glycemic	
index	(LBGI);	high	blood	glycemic	index	(HBGI);	daily	average	of	insulin	delivered	in	units	of	
insulin	(INSULIN);	and	daily	average	of	glucagon	delivered	in	mg	(GLUCAGON).		A	two-week	
scenario	was	 used	 to	 compare	 the	 closed-loop	 insulin-only	 strategy	 (IO),	 the	 coordinated	
bihormonal	controller	(CO)	and	its	non-coordinated	counterpart	(NC).	
	
3. Results	
Table	2,	Table	3	and	Table	4	show,	respectively,	the	results	corresponding	to	the	10	adults,	
10	adolescents,	and	10	children,	plus	the	corresponding	average	subject,	for	the	closed-loop	
insulin-only	strategy	(IO),	the	non-coordinated	bihormonal	control	(NC),	and	its	coordinated	
counterpart	 (CO).	 Figure	 6,	 Figure	 7	 and	 Figure	 8	 show	 the	mean	 plasma	 glucose,	 insulin	
delivery	 and	 glucagon	 delivery	 corresponding	 to	 the	 three	 evaluated	 strategies,	 for	 the	
adult,	 adolescent	 and	 children	 cohort,	 respectively.	Note	 that	 only	 one	week	 of	 data	 has	
been	displayed	in	order	to	enhance	visualization.		
When	compared	against	 the	 insulin-only	 strategy,	both	bihormonal	 strategies	 significantly	
reduce	 hypoglycemia	 in	 all	 cohorts.	While	 the	 non-coordinated	 strategy	 slightly	 increases	
hyperglycemia,	 the	 coordinated	 strategy	 decreases	 it	 in	 the	 adult	 cohort	 and	 remains	
unchanged	 in	 the	 adolescent	 and	 children	 cohorts.	 When	 comparing	 the	 coordinated	
bihormonal	 control	 strategy	 against	 its	 uncoordinated	 counterpart,	 all	 the	 evaluated	
glycemic	metrics	show	a	statistically	significant	 improvement,	or	 remain	unchanged,	apart	
from	the	low	blood	glycemic	index	(LBGI),	which	slightly	increases	in	all	cohorts.	Note	that	
the	improvements	in	the	children	cohort	are	more	moderate	than	the	ones	in	the	adult	and	
adolescent	cohorts.	
	
Table	 2.	 Results	 corresponding	 to	 10	 adults	 plus	 the	 average	 adult	 subject.	 Symbol	 “*”	
indicates	statistical	significance	(p<0.01)	with	respect	to	the	closed-loop	insulin	only	therapy	
(IO)	 and	 symbol	 “‡”	 indicates	 statistical	 significance	 (p<0.01)	 with	 respect	 to	 the	 non-
coordinated	 hormonal	 control	 (NC).	 A	 double	 symbol	 (e.g.	 “‡‡”)	 indicated	 statistical	
significance	of	p<0.05.	
	 Glucose	
mg/dl	
%IN	[70,140]	
mg/dl	
%<70	
mg/dl	
%>140	
mg/dl	
%IN	[70,180]	
mg/dl	
%>180	
mg/dl	
IO	 131.8±5.9	 58.7±6.3	 5.3±2.1	 35.8±5.3	 81.1±6.0	 13.5±5.5	
NC	 136.03±6.8*	 61.37±6.5*	 1.53±1.0*	 37.09±6.4	 84.53±5.7*	 13.93±5.8	
CO	 130.0±5.9*‡	 66.75±5.8*‡	 1.79±1.5*	 31.4±6.0*‡	 88.1±4.7*‡	 10.0±4.9*‡	
	
	 STD	
mg/dl	
RI	 LBGI	 HBGI	 INSULIN	
U	per	day	
GLUCAGON	
mg	per	day	
IO	 42.7±7.3	 4.6±1.3	 1.6±0.7	 2.9±1.0	 41.2±9.2	 0±0	
NC	 38.10±8.0*	 3.48±1.12*	 0.45±0.15*	 3.03±1.11	 43.61±9.92*	 0.64±0.52*	
CO	 35.44±6.89*‡	 2.92±0.84*‡	 0.56±0.24*‡‡	 2.35±0.85*‡	 44.99±10.25*‡	 0.70±0.53*‡	
	
Figure	6.	Upper	graph:	average	plasma	glucose	(adult	cohort)	for	closed-loop	insulin-only	
therapy	(red	solid	line)	vs.	un-coordinated	bihormonal	controller	(blue	solid	line)	vs.	its	
coordinated	counterpart	(green	dashed	line)	(one	week).	Vertical	bars	represent	the	meals.	
Middle	graph:	corresponding	insulin	delivery	without	considering	the	meal	boluses.	Lower	
graph:	corresponding	glucagon	delivery.	
	
Table	3.	Results	corresponding	to	10	adolescents	plus	the	average	adolescent.	Symbol	“*”	
indicates	statistical	significance	(p<0.01)	with	respect	to	the	closed-loop	insulin	only	therapy	
(IO)	 and	 symbol	 “‡”	 indicates	 statistical	 significance	 (p<0.01)	 with	 respect	 to	 the	 non-
coordinated	 hormonal	 control	 (NC).	 A	 double	 symbol	 (e.g.	 “‡‡”)	 indicated	 statistical	
significance	of	p<0.05.	
	
	 Glucose	
mg/dl	
%IN	
[70,140]	
mg/dl	
%<70	
mg/dl	
%>140	
mg/dl	
%IN	
[70,180]	
mg/dl	
%>180	
mg/dl	
IO	 150.4±13.3	 46.4±7.3	 5.0±4.1	 48.5±5.8	 67.9±9.0	 27.0±8.1	
NC	 158.4±10.2*	 45.3±4.3	 1.2±0.9*	 53.3±4.1*	 69.4±6.3	 29.2±6.6*	
CO	 150.9±12.4‡	 49.7±5.1‡	 1.9±1.8*	 48.3±5.9‡	 73.1±7.5*‡	 24.9±8.3‡	
	
	 STD	
mg/dl	
RI	 LBGI	 HBGI	 INSULIN	
U	per	day	
GLUCAGON	
mg	per	day	
IO	 59.7±10.0	 8.2±3.1	 2.0±2.4	 6.1±2.2	 31.1±7.3	 0±0	
NC	 56.7±9.1	 7.1±1.8	 0.4±0.2*	 6.6±1.9*	 33.2±7.9*	 0.50±0.35*	
CO	 53.2±9.8**‡	 6.2±1.8**‡	 0.6±0.5*‡‡	 5.6±2.1‡	 35.0±8.3*‡	 0.6±0.55*‡	
	
	
Figure	7.	Upper	graph:	average	plasma	glucose	(adolescent	cohort)	for	closed-loop	insulin-
only	therapy	(red	solid	line)	vs.	un-coordinated	bihormonal	controller	(blue	solid	line)	vs.	its	
coordinated	counterpart	(green	dashed	line)	(one	week).	Vertical	bars	represent	the	meals.	
Middle	graph:	corresponding	insulin	delivery	without	considering	the	meal	boluses.	Lower	
graph:	corresponding	glucagon	delivery.	
	
Table	4.	Results	corresponding	to	10	children	plus	the	average	children.	Symbol	“*”	
indicates	statistical	significance	(p<0.01)	with	respect	to	the	closed-loop	insulin	only	therapy	
(IO)	and	symbol	“‡”	indicates	statistical	significance	(p<0.01)	with	respect	to	the	non-
coordinated	hormonal	control	(NC).	A	double	symbol	(e.g.	“‡‡”)	indicated	statistical	
significance	of	p<0.05.	
	
	 Glucose	
mg/dl	
%IN	
[70,140]	
mg/dl	
%<70	
mg/dl	
%>140	
mg/dl	
%IN	
[70,180]	
mg/dl	
%>180	
mg/dl	
IO	 163.3±8.9	 44.6±6.39	 3.12±2.61	 52.2±7.66	 65.3±5.39	 31.5±6.40	
NC	 166.5±8.7*	 45.0±6.6	 0.78±0.78*	 54.1±7.1*	 66.8±5.86*	 32.3±6.26	
CO	 162.4±8.7*‡	 47.7±6.7*‡	 1.16±1.05*	 51.0±7.2‡	 68.18±5.38*	 30.6±5.76‡	
	
	 STD	
mg/dl	
RI	 LBGI	 HBGI	 INSULIN	
U	per	day	
GLUCAGON	
mg	per	day	
IO	 68.9±6.32	 8.92±1.34	 0.94±0.78	 7.98±1.43	 17.45±3.78	 0±0	
NC	 65.3±6.3*	 8.31±1.45*	 0.25±0.15*	 8.05±1.50	 17.9±3.79*	 0.44±0.64*	
CO	 65.3±7.4*	 7.98±1.44*‡	 0.38±0.24*‡	 7.59±1.46*‡	 18.3±3.76*‡	 0.56±0.78*‡	
	
	
Figure	8.	Upper	graph:	average	plasma	glucose	(children	cohort)	for	closed-loop	insulin-only	
therapy	(red	solid	line)	vs.	un-coordinated	bihormonal	controller	(blue	solid	line)	vs.	its	
coordinated	counterpart	(green	dashed	line)	(one	week).	Vertical	bars	represent	the	meals.	
Middle	graph:	corresponding	insulin	delivery	without	considering	the	meal	boluses.	Lower	
graph:	corresponding	glucagon	delivery.	
	
	
4. Conclusion	
The	proposed	coordinated	bihormonal	control	strategy,	which	accounts	for	the	potentiation	
effect	of	insulin	secretion	by	plasma	glucagon	levels,	achieves	a	reduction	in	hyperglycemia	
without	 increasing	hypoglycemia,	when	compared	against	an	uncoordinated	strategy.	The	
improvement	in	glycemic	control	is	achieved	at	expenses	of	delivering	slightly	more	insulin	
and	glucagon	delivery,	but	this	is	not	clinically	significant.	
The	 improvements	 seen	 in	 time	 in	 target	 and	 time	 above	 target	 suggest	 that	 the	
coordinated	 approach	 minimises	 rebound	 hyperglycaemia	 from	 glucagon	 administration	
while	the	similarities	in	time	in	hypoglycemia	reflect	that	the	glucagon	controller	is	similarly	
effective	in	both	arms	of	the	in	silico	study.	
It	 is	 important	to	highlight	 the	simplicity	of	 the	tuning	procedure,	which	only	requires	the	
insulin	 sensitivity	 factor	 and	 the	 glucagon	 sensitivity	 factor.	 Although	 the	 glucagon	
sensitivity	 is	not	currently	used	 in	diabetes	management,	 it	 should	become	commonplace	
once	the	utilization	of	glucagon	within	artificial	pancreas	becomes	standard.	
The	 potentiation	 effect	 of	 insulin	 secretion	 by	 plasma	 glucagon	 levels	 is	 only	 one	 of	
coordination	effects	between	 insulin	and	glucagon	secretion.	The	suppression	of	glucagon	
secretion	by	plasma	 insulin	 levels	 is	another	coordination	which	could	be	studied	within	a	
bihormonal	controller.	However,	its	benefit	in	an	artificial	pancreas	using	the	subcutaneous	
route	for	delivery	is	less	obvious.		
Despite	 the	 significant	 uncertainty	 and	 variability	 used	 to	 carry	out	 the	 in	 silico	 testing,	 a	
clinical	trial	is	required	to	validate	the	proposed	technique.	
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